Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Sun Pharma preps for $12-billion Organon bid in biggest overseas pharma M&A by Indian co
Sun Pharma is moving forward with a $12 billion offer for Organon & Co. This acquisition would be the largest for an Indian pharma company. Sun Pharma is finalizing financing for the deal. Organon specializes in women's health. The company is also facing competition from other global consortiums. This move signifies Sun Pharma's ambition to grow in innovative drug research.
Sun Pharma closes in on Organon buy, gets set for $12 billion binding bid
Due diligence is complete, financing banks & advisors picked for biggest cross border pharma M&A by Indian pharma company. 2 other global suitors in fray.
With sights on huge gains, Biocon to scale up AI focus
Biopharma major Biocon is significantly scaling up its adoption of artificial intelligence across its operations, from R&D to manufacturing and procurement. This strategic investment aims to achieve substantial cost savings, accelerate drug development timelines, and enhance its competitive edge in the global market.
Blue Star braces for a slow summer start
The room air-conditioner industry anticipates a challenging summer. Rising costs from global events and delayed heat are impacting sales. Despite these hurdles, a double-digit growth is projected. Consumers might consider budget-friendly options. Demand is expected to pick up as summer progresses, with projections of above-normal temperatures in many areas.
SENSEX slides over 700 points, NIFTY50 opens at 22,838, amid mixed global cues; IndiGo, Max Health down 2% - Upstox
SENSEX slides over 700 points, NIFTY50 opens at 22,838, amid mixed global cues; IndiGo, Max Health down 2%Upstox
Iran war hits India's star investors: Ashish Kacholia, Mukul Agrawal, others see 90% of their stocks lose in 2026
Geopolitical tensions stemming from the Iran conflict triggered a broad market sell-off in the March quarter, significantly impacting India's star investors. Portfolios of Ashish Kacholia, Mukul Agrawal, and others saw a vast majority of their stocks decline, with many experiencing losses exceeding 90% of their holdings. This downturn highlighted the vulnerability of mid- and small-cap stocks during global uncertainty.
Iran, Israel War: The world is on its way to a 'doomsday' gas crisis scenario
Iran War LNG Plant Strikes: After Iranian strikes shut Qatar’s Ras Laffan LNG hub, about 17% of global supply is offline, triggering a deep energy shock. With repairs likely to take years, prices are surging and shortages spreading across Asia, raising risks of industrial slowdown, power crises and a prolonged global gas crunch.
Iran attack wipes out 17% of Qatar LNG capacity; ‘never in my wildest dreams,’ says QatarEnergy CEO
The recent escalation of hostilities has struck a devastating blow to Qatar's energy infrastructure, severely impacting crucial facilities that underpin a large portion of the country’s liquefied natural gas exports. Experts warn that recovery could take years, potentially shaking the foundations of global LNG supplies.
Tata Elxsi sets up offshore tech centre in Pune for AI-driven healthcare solutions
Tata Elxsi launched a global offshore development centre for Tokyo-based Terumo Corporation to enhance cardiac and vascular solutions using AI and GenAI. Shares of Tata Elxsi ended lower on Thursday, March 19, by 4% at ₹4,039.30 on the NSE.
IIT Roorkee inaugurates Ashok Soota Molecular Medicine Facility at BSBE to advance translational biomedical research
IIT Roorkee has launched the Ashok Soota Molecular Medicine Facility, a state-of-the-art platform for advanced biomedical research, drug discovery, and diagnostics. This integrated facility, equipped with advanced instrumentation, will accelerate translational research and contribute to national healthcare priorities and global scientific advancements.
Stock to buy: Jefferies lists 10 reasons to buy its top CRDMO pick Sai Life Sciences
Jefferies has initiated coverage on Sai Life Sciences with a 'Buy' rating and a Rs 1,300 target price, citing its integrated 'follow-the-molecule' model and strong growth outlook. The brokerage highlighted the company's healthy pipeline, global presence, and clean balance sheet as key investment drivers, projecting significant upside potential.
Nomura’s Saion Mukherjee picks Dr Reddy’s as top pharma bet amid semaglutide opportunity
Saion Mukherjee, Managing Director & Head of Equity Research at Nomura says Indian pharmaceutical companies are preparing to tap the opportunity as semaglutide goes off patent. While several large firms such as Sun Pharma, Lupin and Zydus could benefit from the growing diabetes and obesity drug market, Mukherjee highlighted Dr Reddy’s as his top pick in the sector. He said the opportunity will play out across domestic and global markets, with semaglutide likely to become an important growth driver for Indian pharma companies in the coming years.